Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenipatide in Major Depressive Disorder
NCT07412756Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Peptides
- Countries
- 15
01
Overview
A Phase 3 trial of brenipatide in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Started Feb 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07412756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412756.